4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Solid Tumor by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 6570 ongoing clinical trials involving Solid Tumor
Of the 6570 trials,2569 trials are in Phase I
Furthermore, 2208 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Solid Tumor by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Solid Tumor, an oncology condition. The largest number of ongoing clinical trials for Solid Tumor is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Solid Tumor-related drug trials.

National Cancer Institute US: The leading ongoing Solid Tumor related clinical trial sponsor

National Cancer Institute US is the top sponsor for Solid Tumor-related ongoing clinical trials.

University of Texas MD Anderson Cancer Center, AstraZeneca Plc, Bristol-Myers Squibb Co, Pfizer Inc, and F. Hoffmann-La Roche Ltd are among other notable clinical trial sponsors involved in Solid Tumor. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Solid Tumor

Pembrolizumab (Keytruda), Entrectinib (Rozlytrek), and Envafolimab (Enweida) are key marketed drugs involving Solid Tumor.

Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Keytruda is formulated as lyophilized powder for solution, solution concentrate for intravenous route of administration. Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor. Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Pembrolizumab was first approved in 2014 and is marketed globally including in the US, the UK, Australia, France, Germany, China, and Japan by Merck Sharp & Dohme Corp.

Entrectinib (Rozlytrek) belongs to the phenylpiperazines class of compounds, acts as an anti-neoplastic agent. It functions via ALK Tyrosine Kinase Receptor Inhibitor mechanism of action. It is formulated as hard gelatin capsules for the oral route of administration. Rozlytrek is indicated for the treatment of adult and pediatric patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced recurrent solid tumors including pancreatic cancer, thyroid cancer, salivary gland cancer, breast cancer, colorectal cancer, and non-small cell lung cancer, and also indicated for the treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer. Entrectinib was first approved in 2019 and is marketed globally including in the US, the UK, Australia, France, Germany, and Japan by Genentech USA Inc.